FindTrial
Sign In

Study on the Immune Characteristics and Predictive Biomarkers of Omalizumab Response in Chronic Spontaneous Urticaria

Study on the Immune Characteristics and Predictive Biomarkers of Omalizumab Response in Chronic Spontaneous Urticaria

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125995
Enrollment
Unknown
Registered
2026-06-02
Start date
2026-06-30
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic spontaneous urticaria

Interventions

Observation group:None

Sponsors

The Second Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for CSU in the "Chinese Guidelines for the Diagnosis and Treatment of Refractory Chronic Spontaneous Urticaria (2025 Edition)"; 2. Has used or is currently using omalizumab treatment; 3. HIS system data information is complete.

Exclusion criteria

Exclusion criteria: Those whose HIS data are incomplete regarding key information (such as medication records, past medical history, and main observation indicators).

Design outcomes

Primary

MeasureTime frame
Dosing pattern;Drug survival and Discontinuation time;Recurrent time and frequency;Efficacy;Incidence rate of adverse events;—

Countries

China

Contacts

Public ContactZhao Wang

The Second Affiliated Hospital of Xi'an Jiaotong University

wang.zhao@xjtu.edu.cn+86 133 2456 2886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026